Vertaling van "willing to talk about their experience " (Nederlands → Frans) :

To this end, it has issued some guidelines and there is a “press list” of those who are willing to talk about their experience.
Pour y arriver, il a développé des directives et il existe une ‘liste de presse’ de gens qui sont prêts à témoigner.

In order to be efficient, prevention requires among other things the spreading of information, viz. the broadcasting of quality information via the media, colloquia, conferences, and debates. In other words, this involves constantly repeating basic notions, talking about experiences of life and death in which everyone, if they are willing to, can recognise themselves or someone else.
Pour pouvoir agir, une prévention nécessite notamment de l’information: diffuser une information de qualité par les médias, colloques, conférences, débats; c’est-à-dire répéter inlassablement des notions simples, parler d’expériences de vie, de mort dans lesquelles chacun peut, s’il se le permet, se reconnaître ou y reconnaître quelqu’un.

Providing support means above all giving the bereaved the opportunity to talk about the suicide, their dismay, their feelings of guilt, shame, relief and their sense of isolation from their friends and family.
Offrir du soutien signifie surtout donner aux proches l’opportunité de parler du suicide, de la stupéfaction, la culpabilité, la honte, le soulagement et l’isolement par rapport à l’entourage.

- Next, a patient or a relative of a patient visits the class to talk about his or her personal experience with mental health.
- Dans un deuxième temps, un patient ou un parent de patient vient en classe pour parler de son expérience personnelle de la santé mentale.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Putting it differently, what needs doing is setting up a therapeutic alliance with the patients themselves as well as their families, whose skills will have to be used in bringing about a change.
En d’autres termes, il s’agit d’établir une alliance thérapeutique tant avec le patient qu’avec la famille, dont il faudra utiliser les compétences pour parvenir à un changement.